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Background:  Transcatheter aortic valve replacement (TAVR) was approved in 2011 in the US for replacement of the aortic valve in 
patients deemed inoperable due to prohibitive surgical risk. End-stage renal disease (ESRD) patients may represent a particularly high-risk 
group for such procedures.
methods:  We used the Nationwide Inpatient Sample (NIS) database and ICD 9 codes, to evaluate in-hospital all-cause mortality, total 
costs related to hospitalization and mean length of stay for ESRD patients treated with TAVR versus (surgical aortic valve replacement) 
SAVR. To adjust for multiple confounders, we employed a propensity score-adjusted model and all components of the Charlson comorbidity 
index.
results:  Among 404 ESRD patients treated with TAVR (n=53) or SAVR (n=351), 52 (12.9%) patients died during hospitalization. TAVR 
was reserved largely for patients with a higher burden of co-morbidities. In-hospital all-cause mortality with TAVR was 9.4% vs. 13.3% 
for SAVR (p=0.43). Mean total hospitalization cost was lower for TAVR ($292,766) compared with SAVR ($387,785) (p=0.03) and this 
difference persisted in the propensity score-adjusted analysis. Median length of stay was shorter with TAVR in the unadjusted (10 days vs. 
15 days, p=0.005), as well as in the adjusted model (Table 1).
conclusion:  In the first year after regulatory approval in the US, TAVR in ESRD patients had comparable in-hospital mortality, fewer 
hospitalization costs and reduced length of stay compared to SAVR.
Table 1
Pre-Match (n=404) Propensity Score Matched (n=106)
TAVR(N=53) SAVR(N=351) P-value TAVR(N=53) SAVR(N=53) P-value
Baseline 
Characteristics
Mean Age 76.75 62.3 <0.001 76.75 76.51 0.88
Women(%) 43 32 0.09 43.39 41.51 0.84
Caucasian(%) 58.5 51 0.3 58.49 60.38 0.84
CHF(%) 71.69 47.58 0.001 71.69 73.59 0.83
PVD(%) 11.32 11.39 0.98 11.32 11.32 1.00
Stroke/TIA(%) 13.2 13.96 0.88 13.21 13.21 1.00
Outcomes
Death 9.43 13.39 0.43 9.43 8.87 0.44
Total Hospitalization 
Cost ($) 292,766 387,785 0.03 292,766 373,393 0.03
Median Length of Stay 
(Days) 10 15 <0.001 14 35 <0.001
